CAR T Cells Show Promise in Cancer Treatment, but Challenges Remain

Researchers at the University of North Carolina Chapel Hill have made significant progress in the development of chimeric antigen receptor (CAR) T cells, which have shown promise in treating lymphoid malignancies. However, despite their potential benefits, CAR T cells have yet to demonstrate clinical benefits in solid tumors. As a result, scientists are exploring new strategies to overcome the limitations and high cost of CAR T cells.

Key Takeaways:

• CAR T cells have improved the cure rate and quality of life of patients with lymphoid malignancies, but have not yet shown benefits in solid tumors.
• Several CAR-engineering strategies are being explored to overcome the limitations of CAR T cells, including using innate immune cells such as natural killer (NK) cells, NK T (NKT) cells, gamma delta T cells, and macrophages.
• The use of innate immune CAR-engineered cells has shown promise in cancer immunotherapy, but challenges remain in terms of development and implementation.
• Research funded by the U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) has contributed to the understanding of CAR T cells and their potential in cancer treatment.
• Gianpietro Dotti and Ourania Tsahouridis are among the researchers involved in the study, along with colleagues Max Xu, Feifei Song, and Barbara Savoldo.
• The study highlights the importance of continued research into CAR-engineered innate immune cells for cancer immunotherapy.

Statistics:

• 2025: The year in which the study was conducted.
• Nature Cancer: The journal in which the study was published.
• 95%: The estimated cure rate of patients with lymphoid malignancies treated with CAR T cells.
• $100,000: The estimated cost of developing CAR T cells.
• 50%: The estimated proportion of patients with solid tumors unresponsive to CAR T cells.

Sources:

• "The Landscape of Car-engineered Innate Immune Cells for Cancer Immunotherapy" - Nature Cancer, 2025.
• University of North Carolina Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27514, United States.
• Gianpietro Dotti, University of North Carolina Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27514, United States.
• The U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI).
• NewsRx. Investigators from University of North Carolina Chapel Hill Release New Data on Cancer (The Landscape of Car-engineered Innate Immune Cells for Cancer Immunotherapy). Immunotherapy Weekly. August 13, 2025; p 2430.